Article from Good News Network curated by Editor in Chief George Lundberg, MD, who notes:
The U.S. Food and Drug Administration (FDA) has approved the use of Lynparza (olaparib) for treating stage 4 pancreatic cancer patients with hereditary BRCA mutation who have not progressed on platinum therapy. A clinical trial showed prolongation of progression free survival in this subset of patients.
Go to full article published by Good News Network.
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.